شيرين عبد الفتاح ابراهيم الجرجاوي
أستاذ
VITAMIN D THERAPY AMONG EGYPTIAN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS Algergawy, Shereen Title:
• 2017
معلومات البحث
المؤلفون
Algergawy, Shereen
الكلمات المفتاحية
Not Available
المجلة العلمية
Not Available
الناشر
Not Available
المجلد
Not Available
العدد
Not Available
الصفحات
Not Available
publication.type
International
رابط البحث
Not Available
المواد المرفقة
Not Available
الملخص
Background: Vitamin D deficiency is increased among patients with systemic lupus erythematosus (SLE). The vitamin D is a potent regulator of the immune system and may suppress inflammatory responses. Vitamin D may be a safe helper to reduce systemic inflammation in these patients. The objectives of this study were to assess are vitamin D deficiency, the effect of high dose therapy in SLE patients and its relationship with disease activity.
Methods: Data were collected from 120 SLE patients attending out patients clinic Benha faculty of medicine rheumatology department between September 2015 and march 2016, 80 SLE patients with vitamin D therapy as patient group and 40 SLE patients without vitamin D therapy as control group. Serum 25-hydroxyvitamin D concentration and disease activity (SLEDAI) had recorded for both group at baseline and after three months. Patients group received cholecalciferol 50,000 IU once weekly for 3 months. Statistical methods were used to determine the correlation of serum vitamin D level and disease activity both at baseline and at 12 weeks. The 40 control SLE patients didn't receive any vitamin D supplementation during the time of study. The patients and control groups were similar regarding age, body mass index, organ involvement, glucocorticoid dose, use of immunosuppressive drugs.
Results: Vitamin D deficiency (
Methods: Data were collected from 120 SLE patients attending out patients clinic Benha faculty of medicine rheumatology department between September 2015 and march 2016, 80 SLE patients with vitamin D therapy as patient group and 40 SLE patients without vitamin D therapy as control group. Serum 25-hydroxyvitamin D concentration and disease activity (SLEDAI) had recorded for both group at baseline and after three months. Patients group received cholecalciferol 50,000 IU once weekly for 3 months. Statistical methods were used to determine the correlation of serum vitamin D level and disease activity both at baseline and at 12 weeks. The 40 control SLE patients didn't receive any vitamin D supplementation during the time of study. The patients and control groups were similar regarding age, body mass index, organ involvement, glucocorticoid dose, use of immunosuppressive drugs.
Results: Vitamin D deficiency (
